ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest Skin videos · 200+ videos

Playback speed

10 seconds

ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Sapna Patel

64 views

June 19, 2024

Comments 0

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

364 views

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

2.0K views

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

813 views

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

214 views

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

739 views

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

588 views

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

181 views

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

273 views

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

817 views

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

199 views

New

Year in Review 2024 - Melanoma

Oncology 2024 Year in Review

A. van Akkooi

124 views

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

Vanderbilt University Medical Center (VUMC)

D. Johnson

120 views

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

524 views

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

474 views

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

2024 ASCO® Annual Meeting Insights Hub

H. Tawbi

436 views

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

1.0K views

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

423 views

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra

41 views

2024 SMR Congress Insights: Key Takeaways of Important Trials in Mel…

Roswell Park Comprehensive Cancer Center

I. Puzanov

129 views

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

327 views

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

Related Videos

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

ESMO 2024 Summary: Metastatic Melanoma Highlights

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

ESMO 2024 Summary: Developmental Therapeutics Highlights

Advances in the Treatment of Melanoma

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

Year in Review 2024 - Melanoma

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

ASCO® 2024 Summary: "Insights in Melanoma"

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

2024 SMR Congress Insights: Key Takeaways of Important Trials in Mel…

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…